1. Home
  2. ASTE vs CGEM Comparison

ASTE vs CGEM Comparison

Compare ASTE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astec Industries Inc.

ASTE

Astec Industries Inc.

HOLD

Current Price

$48.69

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.77

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTE
CGEM
Founded
1972
2016
Country
United States
United States
Employees
4468
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
904.7M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
ASTE
CGEM
Price
$48.69
$13.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$66.00
$30.13
AVG Volume (30 Days)
217.2K
881.8K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
0.85%
N/A
EPS Growth
784.21
N/A
EPS
0.06
N/A
Revenue
N/A
N/A
Revenue This Year
$14.72
N/A
Revenue Next Year
$5.44
$5.20
P/E Ratio
$809.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.83
$5.68
52 Week High
$65.69
$16.74

Technical Indicators

Market Signals
Indicator
ASTE
CGEM
Relative Strength Index (RSI) 36.12 42.75
Support Level $47.69 $12.41
Resistance Level $49.18 $16.21
Average True Range (ATR) 2.31 0.94
MACD -0.63 -0.16
Stochastic Oscillator 13.73 11.57

Price Performance

Historical Comparison
ASTE
CGEM

About ASTE Astec Industries Inc.

Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: